{
  "id": "5c7a4a31d774d04240000006",
  "type": "list",
  "question": "Which are the problems associated with the use of PD-L1 as immunotherapy biomarker?",
  "ideal_answer": "The use of PD-L1 (B7-H1) immunohistochemistry (IHC) as a predictive biomarker is confounded by multiple unresolved issues: variable detection antibodies, differing IHC cutoffs, tissue preparation, processing variability, primary versus metastatic biopsies, oncogenic versus induced PD-L1 expression, and staining of tumor versus immune cells",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30487198",
    "http://www.ncbi.nlm.nih.gov/pubmed/28472902",
    "http://www.ncbi.nlm.nih.gov/pubmed/28837143",
    "http://www.ncbi.nlm.nih.gov/pubmed/30393621",
    "http://www.ncbi.nlm.nih.gov/pubmed/25695955",
    "http://www.ncbi.nlm.nih.gov/pubmed/27532023",
    "http://www.ncbi.nlm.nih.gov/pubmed/26927720",
    "http://www.ncbi.nlm.nih.gov/pubmed/26778219",
    "http://www.ncbi.nlm.nih.gov/pubmed/29387716",
    "http://www.ncbi.nlm.nih.gov/pubmed/27801734",
    "http://www.ncbi.nlm.nih.gov/pubmed/30419350",
    "http://www.ncbi.nlm.nih.gov/pubmed/26516064",
    "http://www.ncbi.nlm.nih.gov/pubmed/26973128",
    "http://www.ncbi.nlm.nih.gov/pubmed/26501438",
    "http://www.ncbi.nlm.nih.gov/pubmed/29567557",
    "http://www.ncbi.nlm.nih.gov/pubmed/28881780",
    "http://www.ncbi.nlm.nih.gov/pubmed/27229745"
  ],
  "snippets": [
    {
      "text": "PD-L1 expression has shown a positive association with response to PD-1 inhibition in noncentral nervous system (CNS) tumors, e.g., melanoma or non-small cell lung cancer, and is discussed as a potential predictive biomarker for patient selection in these tumor types.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26501438",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In summary, the ongoing clinical studies evaluating the activity of PD-1/PD-L1 inhibitors in glioblastoma need to be complemented with well designed and stringently executed studies to understand the influence of PD-1/PD-L1 expression on therapy response or failure and to develop robust means of PD-L1 assessment for meaningful biomarker development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26501438",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emerging data suggest that patients whose tumors overexpress PD-L1 by IHC have improved clinical outcomes with anti-PD-1-directed therapy, but the presence of robust responses in some patients with low levels of expression of these markers complicates the issue of PD-L1 as an exclusionary predictive biomarker. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25695955",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The use of PD-L1 (B7-H1) immunohistochemistry (IHC) as a predictive biomarker is confounded by multiple unresolved issues: variable detection antibodies, differing IHC cutoffs, tissue preparation, processing variability, primary versus metastatic biopsies, oncogenic versus induced PD-L1 expression, and staining of tumor versus immune cells",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25695955",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "it is not clear whether expression of the ligand PD-L1 is a biomarker for response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26516064",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "\u00a0In conclusion, while PD-L1 expression is often a predictive factor for treatment response, it must be complemented by other biomarkers or histopathologic\u00a0features,\u00a0such as the composition\u00a0and\u00a0amount\u00a0of inflammatory cells in the tumor microenvironment and their functional status.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27229745",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PD-L1 expression is likely an imperfect predictive biomarker for patient selection and association with other markers of the tumor immune microenvironment will be probably necessary in the future.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26778219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26973128",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite impressive treatment outcomes in a subset of patients who receive these immune therapies, many patients with NSCLC fail to respond to anti-PD-1/PD-L1 and the identification of a biomarker to select these patients remains highly sought after. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532023",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However in the multivariate analysis only PD-L1 expression on tumor cells remained significantly associated with pCR (OR = 1,13; 95% CI 1,01-1,27), suggesting that the expression of this biomarker could be associated with a subpopulation of TNBC more likely to respond to chemotherapy. These data need to be confirmed by larger studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29387716",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". Although the most studied biomarker is PD-L1 expression, its clinical significance is still debatable.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28472902",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28881780",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In summary, while the significance of PD-L2 in HNSCC seems to minor, we show that PD-L1 expression is common in HNSCC and, more importantly, a both robust and strong prognostic biomarker. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28881780",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we demonstrate that PD-L1 is currently the best-known biomarker for G3 NENs, becoming the new gold standard for G3 NEN discrimination.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28837143",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Thus, sPD-L1 levels are increased in melanoma patients with severe OSA and, in addition, might serve as a potential biomarker of CM aggressiveness and invasiveness in this group of subjects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30487198",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Programmed cell death ligand-1 (PD-L1), which is a validated biomarker in non-small cell lung cancer (NSCLC), is often also used to select patients for CIT in the context of gastroesophageal cancer, although this marker has not been validated for this purpose. We question the use of PD-L1 as a biomarker in gastroesophageal cancers, as there are fundamental differences in PD-L1 expression between NSCLC and gastroesophageal cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30419350",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PD-L1 expression as a predictive biomarker for immunotherapy in NSCLC patients has shown some value for predicting response to immune checkpoint inhibitors in some studies, but not in others, and its use has been complicated by a number of factors which has prompted many researchers to establish better predictive biomarkers for immunotherapy of NSCLC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30393621",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29567557",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27801734",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Programmed death-ligand 1 (PD-L1) has emerged as a potential target for therapeutics in a number of malignant tumors, including melanoma, lung, and colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27801734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This is becoming a much debated issue, and the immunohistochemical detection of Programmed Death Ligand 1 (PD-L1), the ligand for the inhibitory Programmed Death receptor 1 (PD-1) checkpoint, is one possible biomarker.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927720",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Given that there are 4 such drugs rapidly approaching regulatory approval, each with its own independent PD-L1 immunohistochemistry biomarker test, both oncologists and pathologists face some significant challenges.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26927720",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "low levels of expression, variable detection antibodies, tissue preparation problems, source of expression, staining of tumor cells, immunohistochemistry cutoffs"
}